drugset / Trial / NCT04456608
Genetic and Dietary Predictors of Anti-platelet Response
Phase 4
Terminated
126 enrolled
University of Washington
National Institute of General Medical Sciences (NIGMS) · collabOregon Health and Science University · collabSouthcentral Foundation · collabUniversity of Montana · collab
NaSingle-groupOpen-labelBasic science
Summary
This study will investigate differences in platelet aggregation under basal and aspirin-treated conditions in American Indian and Alaska Native people who have extreme levels (low and high) of n-3 polyunsaturated fatty acids (n-3 PUFAs, EPA and DHA) in red blood cell membranes. The study will also determine whether or not platelet aggregation under the different conditions is modified by CYP4A11, CYP4F2, CYP4F11, PEAR1, and ACTN1 gene variation.
Timeline
- Start
- 2016-08-01
- Primary completion
- 2023-07-31
- Completion
- 2023-07-31
Outcome
Outcome not reported
Stopped (Business): “Funding ended before the study could be completed,”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 81 mg | — |
Indications
No indication recorded.